Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist.
Schröder
Annika K
AK
Department of Gynecology and Obstetrics, University Clinic Hospital, Lübeck, Germany.
Schöpper
Beate
B
Al-Hasani
Safaa
S
Löning
Martin
M
Diedrich
Klaus
K
Ludwig
Michael
M
D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists* / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors*; D006801:Humans; D007248:Infertility, Male / Q000628:therapy*; D008297:Male; D008596:Menotropins / Q000008:administration & dosage; D010062:Ovulation Induction; D011994:Recombinant Proteins / Q000008:administration & dosage; D020554:Sperm Injections, Intracytoplasmic; D013094:Spermatozoa / Q000378:metabolism*; D017329:Triptorelin Pamoate / Q000008:administration & dosage; D015044:Zona Pellucida / Q000378:metabolism*
D011994:Recombinant Proteins; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D005640:Follicle Stimulating Hormone; C062876:cetrorelix